ISL
EPRX

Ingalls & Snyder LLC’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Ingalls & Snyder LLC’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$548K Sell
75,650
-1,750
-2% -$14.1K 0.02% 279
2025
Q4 		$584K Buy
77,400
+18,300
+31% +$113K 0.02% 274
2025
Q3 		$349K Buy
59,100
+21,900
+59% +$119K 0.01% 353
2025
Q2 		$214K Buy
+37,200
New +$143K 0.01% 418

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Ingalls & Snyder LLC's EPRX Position: Q1 2026 in Review

Ingalls & Snyder LLC reduced its Eupraxia Pharmaceuticals (EPRX) stake by 2.3% in Q1 2026, selling an estimated $14.1K and leaving 75,650 shares worth $548K. The position accounts for 0.02% of the portfolio, ranked #279.

Ingalls & Snyder LLC first reported a position in EPRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $584K in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Ingalls & Snyder LLC held 75,650 shares of Eupraxia Pharmaceuticals worth $548K as of Q1 2026.
  • Ingalls & Snyder LLC sold 1,750 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $14.1K.
  • Eupraxia Pharmaceuticals made up 0.02% of Ingalls & Snyder LLC's portfolio in Q1 2026, its #279 holding.
  • Ingalls & Snyder LLC first reported a position in Eupraxia Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Ingalls & Snyder LLC's Eupraxia Pharmaceuticals position peaked at $584K in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2026, filed 13 May 2026.